Citations & References (7)

Invitrogen™

ViraPower™ Adenoviral Gateway™ Expression Kit

Invitrogen’s ViraPower™ Adenoviral Expression Systemでは、複製できないアデノウイルスを使用して、哺乳類細胞の分裂および非分裂にターゲット遺伝子を効率的にin vitroまたはin vivoで導入できます。ViraPower™詳細を見る

製品番号（カタログ番号）	数量
K493000	1 kit

製品番号（カタログ番号） K493000

価格（JPY）

317,900

1 kit

Invitrogen’s ViraPower™ Adenoviral Expression Systemでは、複製できないアデノウイルスを使用して、哺乳類細胞の分裂および非分裂にターゲット遺伝子を効率的にin vitroまたはin vivoで導入できます。ViraPower™ Adenoviral Expression Systemでは、Gateway™組換えクローニングテクノロジーを利用してクローニングを簡素化します。これによって、高力価の組換えアデノウイルス生成の効率が大幅に向上します。このキットには、pAd⁄CMV⁄V5-DEST Gateway™適応型アデノウイルスベクターは、ヒトサイトメガロウイルス（CMV）エンハンサープロモーターの即時早期のエンハンサー⁄プロモーターおよび293A細胞株からの高レベルのタンパク質発現を可能にします。.

主な利点：
•濃縮調製で最大1 x 1011 PFU⁄mLの高力価のアデノウイルス株を生成できます
• 高効率かつ迅速な Gateway™組換えクローニングでは、ヒト細胞または細菌細胞における非効率な相同組換えを回避します
• in vivoで目的の遺伝子を培養内の分裂および非分裂の哺乳類細胞に能動的に効率良く導入します
• ハイスループットのアプリケーションやライブラリ転送アプリケーションに最適です
• 複製できないウイルスにより、システムの生物学的安全性とその遺伝子の導入手段としての使用が向上します

研究用にのみ使用できます。診断用には使用いただけません。

構成または誘導システム構造的

供給タイプアデノウイルス

使用対象（アプリケーション）ウイルス発現

製品タイプAdenoviral Expression Kit

数量1 kit

ベクターpAd

クローニング法Gateway™

製品ラインGateway、ViraPower, ViraPower

プロモーターCMV

タンパク質タグV5エピトープタグ

Unit SizeEach

組成および保存条件

PAdCMV⁄V5-DEST Gateway™ベクター：-20℃で保管
293A細胞：液体窒素で保管してください。
適切に保存した場合、6カ月間安定しています。

よくあるご質問（FAQ）

Can I perform the single-step protocol for the BP/LR Clonase reaction using BP Clonase enzyme and LR Clonase enzyme instead of BP Clonase II enzyme and LR Clonase II enzyme?

In the single-step protocol for the BP/LR Clonase reaction, we would not recommend substituting the BP Clonase II/LR Clonase II enzymes with BP Clonase /LR Clonase enzymes as this would result in very low recombination efficiency.

Do you have a recommended single-step protocol for BP/LR recombination?

Yes, we have come up with a single-step protocol for BP/LR Clonase reaction (http://www.thermofisher.com/us/en/home/life-science/cloning/gateway-cloning.html#1), where DNA fragments can be cloned into Destination vectors in a single step reaction, allowing you to save time and money.

How can I move my gene of interest from a Gateway-adapted expression clone to a new Destination vector as I have lost the entry clone?

We would recommend performing a BP reaction with a Donor vector in order to obtain an entry clone. This entry clone can then be used in an LR reaction with the Destination vector to obtain the new expression clone.

Can I purchase the 5X LR Clonase buffer or 5X BP Clonase buffer separately?

We do not offer the 5X LR Clonase buffer and 5X BP Clonase buffer as standalone products. They are available as part of the enzyme kits.

Do you offer Gateway vectors for expression in plants?

We do not offer any Gateway vectors for expression in plants.

View all ViraPower™ Adenoviral Gateway™ Expression Kit FAQs

引用および参考文献 (7)

引用および参考文献

Abstract

The receptor for parathyroid hormone and parathyroid hormone-related peptide is hydrolyzed and its signaling properties are altered by directly binding the calpain small subunit.

Authors:Shimada M, Mahon MJ, Greer PA, Segre GV,

Journal:Endocrinology

PubMed ID:15691895

'We show calcium-dependent, direct binding between the N-terminal portion of the PTH/PTHrP receptor (PTH1R) C-terminal intracellular tail and the calpain small subunit. Binding requires, but may not be limited to, amino acids W474, S475, and W477. The wild-type, full-length rat (r) PTH1R, but not rPTH1R with W474A/W477A substitutions, copurifies with ... More

p116Rip targets myosin phosphatase to the actin cytoskeleton and is essential for RhoA/ROCK-regulated neuritogenesis.

Authors:Mulder J, Ariaens A, van den Boomen D, Moolenaar WH,

Journal:Mol Biol Cell

PubMed ID:15469989

Activation of the RhoA-Rho kinase (ROCK) pathway stimulates actomyosin-driven contractility in many cell systems, largely through ROCK-mediated inhibition of myosin II light chain phosphatase. In neuronal cells, the RhoA-ROCK-actomyosin pathway signals cell rounding, growth cone collapse, and neurite retraction; conversely, inhibition of RhoA/ROCK promotes cell spreading and neurite outgrowth. The ... More

Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs.

Authors:Happel KI, Lockhart EA, Mason CM, Porretta E, Keoshkerian E, Odden AR, Nelson S, Ramsay AJ,

Journal:Infect Immun

PubMed ID:16113296

Interleukin-23 (IL-23) is a heterodimeric cytokine that shares IL-12 p40 but contains a unique p19 subunit similar to IL-12 p35. Previous studies indicate a greater importance for intact IL-12/23 p40 expression than IL-12 p35 for immunity against Mycobacterium tuberculosis, suggesting a role for IL-23 in host defense. The effects of ... More

Estrogen related receptors stimulate pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression.

Authors:Zhang Y, Ma K, Sadana P, Chowdhury F, Gaillard S, Wang F, McDonnell DP, Unterman TG, Elam MB, Park EA,

Journal:J Biol Chem

PubMed ID:17079227

The pyruvate dehydrogenase complex (PDC) catalyzes the conversion of pyruvate to acetyl-CoA in mitochondria and is a key regulatory enzyme in the oxidation of glucose to acetyl-CoA. Phosphorylation of PDC by the pyruvate dehydrogenase kinases (PDK2 and PDK4) inhibits PDC activity. Expression of the PDK genes is elevated in diabetes ... More

Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A2.

Authors:Murakami M, Masuda S, Shimbara S, Ishikawa Y, Ishii T, Kudo I,

Journal:J Biol Chem

PubMed ID:15863501

Human group III secreted phospholipase A(2) (sPLA(2)-III) consists of a central group III sPLA(2) domain flanked by unique N- and C-terminal domains. We found that the sPLA(2) domain alone was sufficient for its catalytic activity and for its prostaglandin E(2) (PGE(2))-generating functions in various cell types. In several if not ... More

View all ViraPower™ Adenoviral Gateway™ Expression Kit citations